Repligen Corp (RGEN) · Oct 30, 2026 · New debt
Debt refinanced — 0.25% due 2031 replacing 1.00% due 2028
Repligen’s new convertible debt deal lowers the coupon and extends maturity, but missing transaction amounts leave the balance-sheet impact unclear.
Repligen is a growing bioprocessing technology company using its stronger demand backdrop and newly completed BioLife acquisition to expand into cell therapy; after reporting 12.5% organic Q3 growth, it raised 2026 revenue guidance to $844–$852 million. This filing is a financing reset, not an operating update. Repligen is offering 0.25% convertible notes due 2031, with investors able to exchange the existing 1.00% notes due 2028 and/or buy additional new notes for cash. 〔0〕 The clear benefit is cheaper stated interest and three more years before maturity, giving the company more time to integrate BioLife and pursue growth without an immediate cash refinancing need.
The important numbers are missing from the supplied filing. The exhibits referenced for the exchanged principal, purchased principal, and cash purchase price are not included here, and the filing also does not provide the new notes’ conversion rate or premium. That means investors cannot yet determine how much cash Repligen is raising, how much 2028 debt is being retired, or the potential equity dilution. The new notes can be settled partly in shares above principal at Repligen’s election.
The transaction is committed but not yet closed. Settlement is scheduled for November 6, 2026, subject to the stated conditions and delivery of the old notes and/or cash subscription proceeds.
Bottom line: This improves the maturity profile and lowers the coupon, which supports Repligen’s post-BioLife expansion story. But until the transaction amounts and conversion economics are disclosed, the financing’s total balance-sheet and dilution impact remains unresolved.
Closing and settlement expected November 6, 2026
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!